Scarica l'app Stockscreener
24.50
0.45%
0.11
Dopo l'orario di chiusura:
24.47
-0.03
-0.12%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché BEAM Giù?
Forum
Previsione
Beam Therapeutics Inc Borsa (BEAM) Ultime notizie
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Beam Therapeutics Inc.BEAM - PR Newswire
Will IP Theft Allegations Against YolTech and Serapha Bio Change Beam Therapeutics' (BEAM) Narrative - Yahoo Finance
Beam says Chinese firm, Serapha stole trade secrets (BEAM) - Seeking Alpha
Three biotech updates, including accusations of theft and and a new lobbying leader - statnews.com
(BEAM) Movement as an Input in Quant Signal Sets - Stock Traders Daily
Beam sues 2 biotechs, alleging theft of base editing trade secrets - BioPharma Dive
Beam Therapeutics Inc (NASDAQ: BEAM) Share Price, BEAM Stock News, BEAM Share Price & Updates - kalkine.ca
Beam Therapeutics: Ignore The Anthropic Noise And Focus On Clinical Progress (NASDAQ:BEAM) - Seeking Alpha
As Claude Enters the Gene-Editing Arena, There’s Still a Long-Term Case for BEAM Stock - Barchart.com
Beam Says Scientist Stole Secrets for Her Chinese Rival Startup - Bloomberg Law News
PRME Surges 15% After Winning Arbitration Against Beam — Clears Path To Human Trials For Its Gene-Editing Drug - Stocktwits
Beam Therapeutics Inc. (BEAM) stock price, news, quote and history - Yahoo Finance Singapore
Beam Therapeutics (BEAM) president gifts shares to a family trust and retains 130,504 directly. - Stock Titan
Beam Therapeutics Inc. (BEAM) Stock Price, News, Quote & History - Yahoo! Finance Canada
Beam Therapeutics (BEAM) Short Interest & Short Float | Updated Sep 2026 - MarketBeat
Beam Therapeutics (BEAM) Stock Could Trade At A Premium As Gene Editing Interest Grows - Yahoo Finance
BEAM News | BEAM THERAPEUTICS INC (NASDAQ:BEAM) - ChartMill
Cathie Wood Loads Up On Biotech: 5 ETFs Holding Her Latest Bets - Benzinga
Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought - The Motley Fool
Beam Therapeutics Inc. (BEAM) Stock Price | Live Quotes & Charts | NASDAQ - timothysykes.com
Can Intellia's Pipeline Progress Create Long-Term Value Amid Rivalry? - tradingview.com
Beam Therapeutics faces securities fraud probe after trial data reveals safety concerns, stock drops 9.5%. - Pluang
BEAM Investors Have Opportunity to Join Beam Therapeutics Inc. Fraud Investigation with SBS Law - Business Wire
Clinical Trial Progress Might Change The Case For Investing In Beam Therapeutics Stock (BEAM) - webull.com
Beam Therapeutics: Market Selling Phase 2 AATD Data Is Understandable, In My View - Seeking Alpha
Beam Therapeutics faces securities fraud probe after clinical trial safety concerns cause stock to drop 9.5%. - Pluang
Beam Therapeutics (BEAM) Restored AAT Levels. Can BEAM-302 Deliver Clinical Benefit? - Yahoo Finance
Beam Therapeutics Inc. (BEAM) Discusses Updated Phase 1/2 Data for BEAM-302 in Alpha-1 Antitrypsin DeficiencySlideshow (NASDAQ:BEAM) 2026-09-10 - Seeking Alpha
Beam Therapeutics Inc. (BEAM) Presents at European Respiratory Society (ERS) CongressSlideshow - Seeking Alpha
Beam Therapeutics at cantor conference: base editing lead comes into focus - Investing.com Canada
Cathie Wood’s ARK sells Alphabet stock, buys Meta and Beam Therapeutics - Investing.com
Beam Therapeutics at Citi summit: platform gains momentum across pipeline By Investing.com - Investing.com India
Transcript : Beam Therapeutics Inc. Presents at Citigroup?s Biopharma Back to School Summit 2026, Sep-09-2026 01 - marketscreener.com
Why (BEAM) Price Action Is Critical for Tactical Trading - Stock Traders Daily
A Quick Look at Today's Ratings for Beam Therapeutics(BEAM.US), With a Forecast Between $35 to $80 - Moomoo
BEAM Stock Price, Quote & Chart - ChartMill
BEAM Reiterated by Wedbush -- Price Target Maintained at $65 - GuruFocus
BofA Securities Maintains Beam Therapeutics(BEAM.US) With Buy Rating, Maintains Target Price $43 - Moomoo
BEAM Looks 14.6% Overvalued on GF Value™ - GuruFocus
Beam Therapeutics at Wells Fargo conference: base editing gains ground By Investing.com - Investing.com India
Beam drops after updating Phase 1/2 trial data for gene-editing drug - Seeking Alpha
3 Promising Genomics Stocks in the Spotlight in 2026 - TradingView
BEAM - Finviz
Beam Therapeutics Targets Accelerated FDA Approval for Base-Editing Treatment - Yahoo Finance
Beam Therapeutics reports BEAM-302 AATD trial update - grafa.com
BEAM Looks 26.9% Overvalued on GF Value™ - GuruFocus
Beam Therapeutics Presents Updated Clinical Data from the Phase 1/2 Trial of BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD) at the European Respiratory Society (ERS) Congress 2026 - manilatimes.net
Beam Therapeutics Presents Updated Clinical Data from the - GlobeNewswire
Beam Therapeutics (BEAM) Stock Analysis Report | Ratings, Financials & Performance - Benzinga España
BEAM Stock Price and Chart — NASDAQ:BEAM - TradingView
BEAM Should I Buy - Intellectia AI
Beam Therapeutics appoints Eric Foster as CCO - The Pharma Letter
Beam Therapeutics names Eric Foster as chief commercial officer By Investing.com - Investing.com Nigeria
Beam Therapeutics names Eric Foster as chief commercial officer - Investing.com
0.05%
0.82%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):